Name: Angiochem Inc. - BioCentury Company Profiles - BCIQ
Creator: Biocentury

signInButton

SIGN IN

Find partnering and investment opportunities, uncover and track competitive threats, dive into a company's financing and deal history, its pipeline and molecular targets of interest, and much more. Please note, you are viewing a free version of BCIQ, BioCentury's advanced business intelligence database for the biopharma industry. Request a trial to unlock the full value of BCIQ.

REQUEST A FREE TRIAL

AcquiredOrMerged

Company profiles have been archived if there have been no financings, deals or product updates in BCIQ in the last five years, or the company is out of business.

If you believe a company has been archived in error, please contact us at 

Company profiles have been archived if there have been no financings, deals or product updates in BCIQ in the last five years, or the company is out of business.\nIf you believe a company has been archived in error, please contact us at \nsupport@biocentury.com\n.

Cat-H(AcquiredorMerged)

Historical deals and financings can be found by searching the organization's name in the BCIQ <DEALS> and <FINANCING> Modules.

Default (Company Type Blank)

CategoryHDefault (Company Type Blank)

NonBioPharma

Biopharma related deals can be found by searching the organization's name in the <DEALS> Module.

Cat-H(NonBioPharma)

Biopharma related deals can be found by searching the organization's name in the <DEALS> Module.\n

Angiochem Inc.

Aug. 6 Company Quick Takes: Sales updates from Alnylam, Sage, Regeneron and GW; plus regulatory updates from MorphoSys and more

Angiochem grants Xinogen Chinese rights to ANG1005

Angiochem, Xinogen in China deal

Breaching the gates

ANG1005: Interim Phase II data

Therapeutics: Epidermal growth factor receptor 2 (EGFR2; HER2; ErbB2; neu)

Angiochem preclinical data

Signal crossing

ANG1005: Phase II started

Indication: Neurology